Vast Awarded $2 Million Grant to Combat Deadly Respiratory Bacteria
FundsfromNIHwilladvance ALX1asapotentialtreatment in Cystic Fibrosis and other chronic lung diseases Vast Therapeutics, a clinical-stage life science company, today announced that it has been awarded a nearly two million dollar grant from the National Institutes of Health (NIH).1Thetwo-yearproject aimstoadvance ALX1asabreakthroughtreatmentforpatients worldwide who suffer life altering consequences from chronic lung infections caused by the deadly bacteria Pseudomonas […]